Novogen Limited (ASX:NRT; NASDAQ:NVGN) has identified a family of compounds with an ability to promote the growth and activity of normal brain stem cells.
This is in line with its approach of seeking drugs that would promote the migration of stem cells to the site of injury rather than through the introduction of externally cultured tissue stem cells.
This is a key proof-of-concept step forward in its regenerative medicine program to develop drugs capable of stimulating the function of brain tissue stem cells.
In April 2014, Novogen established a partnership with Genea Biocells, an Australian company with world-leading expertise in the production, growth and development of human embryonic stem cells.
The original purpose of that collaboration was to mine the company’s super-benzopyran drug technology platform for new therapies with the capacity to repair aberrant stem cells in people with various neurodegenerative disorders (eg. motor neurone disease) and musculodegenerative disorders (eg. Muscular dystrophies).
That program recently was extended to look at the ability of that same drug platform to stimulate the growth of healthy brain stem cells to create new nerve cells.
While the company is focused on developing anti-cancer drugs, this discovery demonstrates the potential of its intellectual property across many areas of medicine.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.